STEPHY.T.P, et al. “Comparison of Quality of Life (QOL) for Patients With Breast Cancer Receiving Adjuvant Tac (docetaxel, Doxorubicin, Cyclophosphamide) and Fac (5-Fluorouracil, Doxorubicin, Cyclophosphamide) Therapy”. International Journal of Pharma and Bio Sciences, vol. 8, no. 3, Sept. 2017, pp. 373-82, doi:10.22376/ijpbs.2017.8.3.p373-382.